|
Match
|
Document |
Document Title |
|
|
7381407 |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods...
|
|
|
7378091 |
Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the...
|
|
|
7361347 |
Cytotoxic CD44 antibody immunoconjugates
The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy.
|
|
|
7339033 |
PRO1481
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7332164 |
Heterobifunctional polymeric bioconjugates
Heterobifunctional polymeric prodrug platforms for delivering biologically active compounds, including proteins, monoclonal antibodies and the like are disclosed. One preferred compound is
...
|
|
|
7319139 |
TAG-72 specific CH2 domain deleted antibodies
Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may...
|
|
|
7318924 |
Antibodies against cancer
An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell...
|
|
|
7311892 |
Multidrug multiligand conjugates for targeted drug delivery
Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite...
|
|
|
7307154 |
DNA encoding a novel RG1 polypeptide
The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors...
|
|
|
7303749 |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for...
|
|
|
7285269 |
Antibodies directed to tumor necrosis factor
Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid...
|
|
|
7253263 |
Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3
The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and...
|
|
|
7238785 |
RS7 antibodies
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more...
|
|
|
7227002 |
Human antibodies that bind human 17-A1/EpCAM tumor antigen
The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens,...
|
|
|
7226596 |
Compositions and methods for the treatment of tumors
The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the...
|
|
|
7220414 |
Degradable polyacetal polymers
Degradable polyacetal polymers and functionalized degradable polyacetal polymers have properties favorable for use in pharmaceutical and biomedical applications. The degradable polyacetal polymers...
|
|
|
7217799 |
Antibodies that recognize the 85P1B3 protein useful in treatment and detection of cancer
A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers...
|
|
|
7189824 |
Tumor vessel endothelial cell-binding monoclonal antibodies
A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing the monoclonal antibody,...
|
|
|
7189397 |
Cytotoxicity mediation of cells evidencing surface expression of CD44
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease...
|
|
|
7183388 |
Anti-MUC-1 single chain antibodies for tumor targeting
This invention provides novel antibodies that specifically bind to the cancer antigen MUC-1. The antibodies are useful targeting moieties for specifically directing imaging agents and various...
|
|
|
7148038 |
Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung,...
|
|
|
7138122 |
Therapeutic systems
A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity...
|
|
|
7125554 |
Engineered superantigen for human therapy
The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial...
|
|
|
7125541 |
Combined methods for tumor vasculature targeting and tumor treatment with radiotherapy
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects,...
|
|
|
7122189 |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
Activated polymeric bicine derivatives such as
as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
|
|
|
7115265 |
Four genetic tumor markers specific for human glioblastoma
ABCC3, GPNMB, NNMT, and SEC61γ are expressed at higher levels in glioblastoma than in normal brain tissue. These four genes and their expression products are useful for diagnosing and treating...
|
|
|
7112317 |
Combined methods and compositions for tumor vasculature targeting and tumor treatment
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects,...
|
|
|
7108846 |
Methods for preparing perfluorinated [18f]-radiolabelled nitroimidazole derivatives for cellular hypoxia detection
The present invention relates to chemical synthesis of radiolabelled perfluorinated bioactive compounds. More particularly, the present invention relates to radiolabelled compounds to be used as...
|
|
|
7105149 |
Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein. Provided too, are the...
|
|
|
7097839 |
ST receptor binding compounds and methods of using the same
Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or...
|
|
|
7097835 |
Immunoselective targeting agents and methods of use thereof
The present invention provides immunoselective targeting agents that bind to transporters that are transiently accessible on the surface of neuronal cells, and that deliver compounds selectively to...
|
|
|
7094404 |
Method for treating malignancy and autoimmune disorders in humans using tac antibodies
The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft...
|
|
|
7090844 |
Use of antibodies against the MUC18 antigen
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the...
|
|
|
7087229 |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
Activated polymeric bicine derivatives such as,
as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
|
|
|
7081518 |
Anti-mesothelin antibodies having high binding affinity
Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present...
|
|
|
7070778 |
Therapeutical combination against cancer
The present invention relates to compositions and methods for treating humans and warm-blood animals suffering from cancer. More particularly, a therapeutical treatment in which a monoclonal...
|
|
|
7067131 |
Methods for using anti-MUC18 antibodies
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the...
|
|
|
7060272 |
Death domain containing receptor-4 agonist antibodies and methods
The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid...
|
|
|
7045605 |
Modified antibodies to prostate-specific membrane antigen and uses thereof
Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or...
|
|
|
7033767 |
Genes regulating programmed cell death
The present invention to amino acid sequences of proteins that are associated with apoptosis and the use of these proteins in the diagnosis, prevention and treatment of disorders associated with...
|
|
|
7012135 |
Biological products
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein...
|
|
|
6953568 |
Targeting of molecules to large vessel endothelium using EPCR
Endothelial protein C receptor (EPCR) is found primarily on endothelial cells of large vessels. EPCR translocates from the plasma membrane surface to the nucleus. Molecules which bind to EPCR can...
|
|
|
6946129 |
Recombinant anti-CD40 antibody and uses thereof
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
|
|
|
6926896 |
Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof
The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these...
|
|
|
6924360 |
Antibodies against the MUC18 antigen
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the...
|
|
|
6893625 |
Chimeric antibody with specificity to human B cell surface antigen
A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production,...
|
|
|
6863887 |
Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered...
|
|
|
6843989 |
Methods for the treatment and prevention of cancer using anti-CD40 antibodies
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
|
|
|
6838089 |
Antigen delivery system and method of production
The present invention concerns polymer particle vaccine delivery systems in which a water insoluble protein antigen, e.g. a lipidated HpaA protein, is incorporated with particles comprising a...
|
|
|
6759509 |
Branched peptide linkers
Conjugates containing a targeting ligand, such as an antibody, a therapeutically active drug and a branched peptide linker. The branched peptide linker contains two or more amino acid moieties that...
|